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Abstract
Background: Offspring of at least 1 parent with type 2 diabetes are more resistant to the insulin
action, exhibit higher incidence of dyslipidemia and are more prone to cardiovascular diseases. The
association between Lp(α) and coronary heart disease is well established. An association between
Lp(α) concentration and insulin sensitivity was examined in this study.
We investigated the serum LP(α) in 41 offspring of 41 families of type 2 diabetic subjects (group I)
with normal glucose tolerance, compared to 49 offspring who their parents had no history of type
2 diabetes, matched for sex, age, BMI, WHR and blood pressure (group II). Serum Lp(α),
triglycerides, insulin resistant index, HDL, LDL-cholesterol and insulin were measured.
Results: The offspring of type 2 diabetic subjects had higher fasting serum triglycerides (mean ±
SD 199.3 ± 184.2 vs. 147.1 ± 67.9 ng/dl, p < 0.05) lower HDL-cholesterol (37.3 ± 9.0 vs. 44.6 ±
7.8, p < 0.001) and particularly higher Insulin resistance Index (HOMA-IR) (2.84 ± 1.39 vs. 1.67 ±
0.77, p < 0.001).
They also had higher serum LP(α) concentration (15.4 ± 6.7 vs. 8.6 ± 6.0, p < 0.001). By simple
linear analysis in the offspring of type 2 diabetic parents there was no correlation of Lp(α)
concentration with insulin resistance index Homa-IR (r = 0,016 p = NS).
Conclusions: We conclude that serum LP(α) is significantly increased in offspring of type 2
diabetic subjects but was not related to insulin sensitivity.
Background
Patients with type 2 diabetes mellitus are characterized by
resistance to insulin-stimulated glucose uptake [1,2], dys-
lipidemia (especially increased triglyceride and decreased
high-density lipoprotein (HDL) levels [3,4], hypertension
[5] and coronary heart disease [6,7].
Lipoprotein (α) [Lp(α)], first described by Berg [8] in
1963, is a low density lipoprotein (LDL) – like substance
with a specific apoprotein, apoprotein (α) [apo (α)],
bound to apo-β 100 by disulfide bridges [9,10].
Numerous studies have suggested that lipoprotein (α)
concentrations may be an independent risk factor for cor-
onary heart disease [11–15]. However, the molecular
mechanism by which Lp(α) might promote atherosclero-
sis has not been clarified.
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The relationship of Lp(α) concentrations with insulin
resistance remains controversial. Some studies have
showed increase Lp(α) concentration in subjects with
NIDDM [16–18] whereas other studies have showed sim-
ilar Lp(α) concentrations in type 2 diabetic subjects com-
pared with normoglycemic subjects[19]. In other studies
of nondiabetic subjects, insulin concentrations have not
been associated with Lp(α) concentrations [20,21]. One
study showed no elevated Lp(α) concentrations in nor-
moglycemic insulin-resistant subjects [22].
In this report, we examine the association of Lp(α) con-
centrations to insulin sensitivity, calculated using the
Homeostasis model Assessment (HOMA-IRI) in normo-
glycemic offspring of at least 1 parent with type 2 diabetes.
Results
The clinical characteristics of the study population are
shown in Table 1 and the laboratory profile of the study
population are shown in Table 2.
The group of offspring with type 2 diabetes parents as well
as the control group had a similar distribution of age, sex,
BMI, WHR systolic and diastolic BP. As expected the mean
fasting serum triglycerides, cholesterol, and LDL-choles-
terol were significantly higher in group 1 compared to the
control group. HDL-cholesterol was significantly lower in
group 1 compared to the control group.
The glucose and insulin concentrations in the fasting state
and after an oral glucose challenge are shown in Table 3.
The mean fasting glucose and insulin concentrations were
significantly higher in group I compared to group 2:
fasting glucose: 4.5 ± 0.6 vs. 4.3 ± 0.6 mmol/l (p < 0.05)
fasting insulin: 14.0 ± 6.4 vs. 8.6 ± 3.2 µU/ml (p < 0.005)
Serum insulin concentration 30 min post glucose chal-
lenge was significantly higher in the offspring group 1
(122.2 ± 94.3 vs. 81.7 ± 51.6 µU/ml, p < 0.005) as well at
60 min post glucose challenge (134.4 ± 103.1 vs. 99.9 ±
48.9 µU/ml, p < 0.05) whereas there was no difference at
120 min.
In the offspring of the diabetic parents the insulin resist-
ance index was significantly higher compared to control
group (2.84 ± 1.39 vs. 1.67 ± 0.77, p < 0.001). 22 (53.6%)
of the 41 subjects of group 1, had HOMA-IR values > 2.5
indicating that they were insulin resistant [23–29], com-
pared to only 6 (12.2%) of the 49 subjects of group 2.
Lp(α) concentration was significantly higher in group 1
compared to group 2 (15.4 ± 6.7 vs. 8.6 ± 6.0 ng/dl, p <
0.001).
In the offspring of the diabetic parents the insulin resist-
ance index was positively correlated with serum triglycer-
Table 1: Clinical characteristics of the offspring of type 2 diabetes parents (Group 1) and offspring of normal parents (Group 2).
Parameter Group 1 Group 2 P value
Number (M/F) 41 (28/13) 49 (31/18) NS
Age (Yr) 41.4 ± 6.8 43.5 ± 5.5 NS
BMI (Kg.m-2) 28.1 ± 4.8 27.6 ± 3.5 NS
WHR 0.87 ± 0.1 0.8 ± 0.08 NS
Systolic BP (mmHg) 119.4 ± 15.5 120.8 ± 10.8 NS
Diastolic BP (mmHg) 72.1 ± 12.8 73.9 ± 10.1 NS
Table 2: Laboratory profile of the offspring of type 2 diabetes parents (Group 1) and offspring of normal parents (Group 2).
Parameter Group 1 Group 2 P value
Triglyceride (mg/dl) 199.3 ± 184.2 147.1 ± 67.9 < 0.05
Cholesterol (mg/dl) 215.4 ± 41.6 199.2 ± 29.8 < 0.05
HDL-cholesterol (mg/dl) 37.3 ± 9.0 44.6 ± 7.8 < 0.001
LDL-cholesterol (mg/dl) 143.7 ± 31.7 124.6 ± 25.1 < 0.01
Lp(α) (mg/dl) 15.4 ± 6.7 8.6 ± 6.0 < 0.001Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/8
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ides and LDL. There was no correlation of HOMA-IR with
any of the above parameter in the control group (Table 4).
There was no correlation of HOMA-IR with Lp(α) concen-
tration in the offspring of the diabetic parents.
Discussion
Resistance to insulin-stimulated glucose uptake is a char-
acteristic finding in patients with type 2 diabetes [1,2].
The observation that concordance for type 2 diabetes
approaches 100% when one identical twin has the dis-
ease, strongly suggests that the decisive component of this
syndrome is genetic in nature [30]. Several studies have
shown that offspring of at least one parent with type 2 dia-
betes display hyperinsulinism and are more resistant to
insulin action than offspring of parents whose glucose tol-
erance was normal [31–34].
The result of our study supports and expands those find-
ings. We found that offspring of patients with type 2 dia-
betes when compared with normal individuals whom
their parents had no history of type 2 diabetes matched
for sex, age and BMI, were relative hyperinsulinemic, had
higher fasting serum triglycerides, lower HDL-cholesterol
and higher insulin resistance index.
Moreover, the serum Lp(α) concentration was signifi-
cantly higher compared with control group. The overall
impression from the large number of publications on dia-
betes mellitus and Lp(α), is that neither insulin depend-
ent nor non-insulin dependent diabetes has a direct effect
on serum Lp(α) [16–19,31–34]. Some reports of
increased levels in non-insulin dependent diabetes may
result from the inclusion of patients with established
CHD in the population studied. However, there does
appear to be an increase in serum Lp(α) in insulin-
dependent diabetes when nephropathy is present and this
may be the case even when this is at the stage of micro-
albuminuria [35–42]. Thus the rise seems to occur with
much less marked proteinuria than in primary renal dis-
ease. Possibly this is because there is some specific feature
of the nephropathy in diabetes, which triggers the Lp(α)
response early in the disease or perhaps microalbuminu-
ria in diabetes is a marker for a more extensive vasculopa-
thy which is the major stimulus for Lp(α) to increase.
Table 3: Serum insulin and glucose and insulin resistance index in offspring and control subjects in the fasting state and after an oral 
glucose challenge (120 min)
Group 1 no 41 Group 2 no 49 P value
Glucose (mmol/l)
Fasting 4.53 ± 0.62 4.26 ± 0.56 0.036
30 min 8.4 ± 2.0 8.3 ± 1.5 NS
60 min 8.4 ± 3.0 8.9 ± 2.5 NS
120 min 5.4 ± 1.3 5.6 ± 1.2 NS
Insulin (µU/ml)
Fasting 14.0 ± 6.4 8.6 ± 3.2 < 0.001
30 min 122.2 ± 94.3 81.7 ± 50.6 0.013
60 min 134.4 ± 103.1 99.9 ± 48.9 0.042
120 min 76.9 ± 8.1 70.5 ± 40.7 NS
Insulin Resistance Index (HOMA-
IR)
2.84 ± 1.39 1.67 ± 0.77 < 0.001
Table 4: Correlation (r) and significance (P) of HOMA-IR with serum concentration of Lipids and Lp(α).
Parameter Group 1 Group 2
r P value r P value
Cholesterol 0.177 NS 0.231 NS
Triglycerides 0.319 p < 0.01 0.099 NS
HDL 0.304 p < 0.05 0.055 NS
LDL 0.342 p < 0.02 0.161 NS
Lp(α) 0.016 NSLipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/8
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There has been little published data on insulin sensitivity
and Lp(α) concentrations. Lp(α) concentrations were not
significantly related to insulin sensitivity measured by the
intravenous glucose tolerance test in nondiabetic subjects
[43]. Haffner et al [22] demonstrated that insulin-resist-
ant normoglycemic men did not have elevated Lp(α) con-
centrations and that Lp(α) concentrations are principally
controlled at the locus encoding apo (α) in agreement
with the data of other studies [44–47].
Moreover, Haffner et al suggested that the relationship
between insulin sensitivity and Lp(α) concentrations
might be at least partially dependent on apo (α) pheno-
type [22]. One possibility for such an association could be
that genes for apo (α) genotype and insulin sensitivity
could be in linkage disequilibrium.
To our knowledge this is the first report in which the levels
of Lp(α) concentration and insulin sensitivity in normo-
glycemic offspring of type 2 diabetic parents were studied.
Our study demonstrates that Lp(α) concentrations were
not significantly correlated with HOMA-IR (r = 0.016).
The impression from this finding and in agreement with
previous studies [16,19–21,35–43], is that serum Lp(α)
concentration is not related to insulin sensitivity. How-
ever, Lp(α) concentration was significantly higher in the
group of offspring of diabetic parents compared to the
control group (p < 0.001)
Conclusions
We conclude that serum LP(α) is significantly increased in
offspring of type 2 diabetic subjects but was not related to
insulin sensitivity.
Methods
Subjects
We studied 54 healthy offspring of 54 separate families
with type 2 diabetes parents. The subjects were Caucasians
of Greek origin. They all had a parent who had developed
type 2 diabetes mellitus after 50 years of age. Two patients
were the offspring whom both parents were diabetic.
Maturity-onset diabetes of the young was excluded on the
basis of the late onset of diabetes. The 54 subjects (group
1) were matched to 54 subjects with no family history for
diabetes and were used 95 controls (group 2). The sub-
jects in both groups were matched for sex, age, Body Mass
Index (BMI) and waist-to-hip ratio (WHR).
All subjects had normal physical examination and normal
values for routine laboratory parameters including hema-
tology, c-reactive protein, HbA1c (upper limit of normal
6.5%), adrenal, kidney, liver and thyroid function. The
subjects were not under any medication known to affect
carbohydrate or lipoprotein metabolism and all denied
alcohol intake.
After an appropriate carbohydrate diet for one week, an
oral Glucose Tolerance test (OGTT) was performed and
patients with impaired glucose tolerance or type 2 diabe-
tes were excluded from the study. Forty one subjects
remained for group 1 and 49 for group 2. Informed con-
sent was obtained from all participants in the study.
Study design
After 12-h overnight fast, blood samples were drawn for
serum glucose, insulin, lipids, lipoprotein and Lp(α). The
subjects then ingested 75 g of glucose load over a 2-min
period. Blood samples were drawn at 30, 60 and 120 min
thereafter for measurement of serum glucose and insulin
concentrations. Plasma glucose was measured with an
automatic analyzer by the glucose oxidase method.
Immunoreactive insulin (IRI) was measured with an insu-
lin radioimmunoassay (RIA) kit.
We used the homeastatic model to assess insulin resist-
ance, where HOMA-IR = fasting plasma insulin (µU/ml) ×
fasting plasma glucose (mmol/l) / 22.5 [23–25]. HOMA-
IR provides a reliable estimate of insulin resistance across
the range of glucose tolerance using either the frequently
sampled intravenous glucose tolerance test (FSIGTT) with
minimal model analysis or the glucose clamp technique
as the gold standard measure of insulin sensitivity
[26,27].
Total serum cholesterol, serum triglyceride and HDL-cho-
lesterol were assayed with a commercial kit (Boehringer
Mannheim, Germany). LDL cholesterol was calculated
according to the Friedewald education [28]. Lp(α) was
estimated by enzyme immunoassay (Macra Lp(α), Strate-
gic Diagnostic, Newark, NJ).
The study design was approved by the ethical and scien-
tific committee of the Hospital.
Statistical analysis
Results are expressed as mean ± SD. Data were analyzed
according to the unpaired student's t-test or by the non-
parametric Mann-Whitney U test of Wilcoxon's test. Pear-
son's correlation coefficient or the Spearn's test were used
depending on the normal distribution of the variables. A
p-value of less than 5% was considered statistically
significant.
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